A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Precision NextGen Oncology and Research Center, Beverly Hills, California Sarcoma Oncology Center, Santa Monica, California MD Anderson Cancer Center, Houston, Texas Australia
Chris O'Brien Lifehouse, Sydney, New South Wales Linear Clinical Research, Perth, Western Australia United Kingdom
Leicester Royal Infirmary, Leicester University College London Hospital, London Churchill Hospital, Oxford Last updated September 2025